Press Releases

Home » Press Releases
  • PSYENCE GROUP ANNOUNCES DTC ELIGIBILITY APPROVAL IN THE U.S.

Psyence Group Announces DTC Eligibility Approval in the U.S

2022-02-09T12:56:58+00:00February 9, 2022|Press Releases|

TORONTO, 09 February 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that the Company’s common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States (“US”).

  • PSYENCE_UPDATE_FEATURE

Psyence looks to expand capital market opportunities in the UK and Europe

2022-01-21T16:03:46+00:00January 21, 2022|Press Releases|

TORONTO, DATE, 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is investigating capital market opportunities to access a broader pool of United Kingdom (“UK”) and European investors. This includes a potential dual listing in the UK.

Psyence Group Functional Mushroom Brand “GOODMIND™” Commences National Roll-Out In South Africa’s Largest Coffee Retail Chain

2021-12-02T15:19:55+00:00December 2, 2021|Press Releases, Investor Information, Psychedelic News|

Psyence is pleased to announce that its joint venture functional mushroom brand GOODMINDTM has partnered with one of Africa’s largest coffee retail chains, “vida e caffè”, to commence the rollout of its GOODMINDTM functional mushroom brand in select vida e caffè’s coffee shops in South Africa.

  • Global Wellness Summit - Psilocybin - Boston

Psyence Group Invited as First Psychedelic Company to present at the 15th-Annual Global Wellness Summit

2021-11-27T05:48:16+00:00November 26, 2021|Press Releases, Investor Information, Psychedelic News|

Psyence’s Head of Corporate Social Responsibility, Mary-Elizabeth Gifford, will host an in-person keynote conversation with Rick Doblin, PhD, Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) on the future of Psychedelics and Healing. 

Go to Top